What ArriVent BioPharma, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 1 |
| Total trades | 5 | 6 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 40,693 | 40,693 |
| Disposed | 0 | 555,555 |
| Net activity | +40,693 | −514,862 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer | Oct 30 | Exercise / conversion · M | +17,648 | $6.24 | +$110K | 176,429 |
| LaChapelle Robin | Chief Operating Officer | Oct 30 | Exercise / conversion · M | +1,820 | $2.28 | +$4.15K | 158,781 |
| LaChapelle Robin | Chief Operating Officer | Oct 30 | Exercise / conversion · M | +4,550 | $2.28 | +$10.4K | 156,961 |
| LaChapelle Robin | Chief Operating Officer | Oct 30 | Exercise / conversion · M | +410 | $2.28 | +$935 | 152,411 |
| LaChapelle Robin | Chief Operating Officer | Oct 30 | Exercise / conversion · M | +16,265 | $3.65 | +$59.4K | 152,001 |
| Hillhouse Investment MANAGEMENT, Ltd. | 10% owner | Dec 10 | Open-market sale · S | −555,555 | $23.37 | −$13M | 3,929,117 |
| LaChapelle Robin | Chief Operating Officer | Jul 11 | Exercise / conversion · M | +6,503 | $2.28 | +$14.8K | 135,736 |
| LaChapelle Robin | Chief Operating Officer | Jul 11 | Exercise / conversion · M | +2,600 | $2.28 | +$5.93K | 129,233 |
| LaChapelle Robin | Chief Operating Officer | Jul 11 | Exercise / conversion · M | +2,050 | $2.28 | +$4.67K | 126,633 |
| LaChapelle Robin | Chief Operating Officer | Sep 19 | Exercise / conversion · M | +12,364 | $3.65 | +$45.1K | 124,583 |
| LaChapelle Robin | Chief Operating Officer | Sep 19 | Exercise / conversion · M | +2,471 | $2.28 | +$5.63K | 112,219 |
| LaChapelle Robin | Chief Operating Officer | Sep 19 | Exercise / conversion · M | +7,164 | $2.28 | +$16.3K | 109,748 |
| LaChapelle Robin | Chief Operating Officer | Sep 19 | Exercise / conversion · M | +2,867 | $2.28 | +$6.54K | 102,584 |
| LaChapelle Robin | Chief Operating Officer | Sep 19 | Exercise / conversion · M | +2,700 | $6.24 | +$16.8K | 99,717 |
| Gordon Carl L | Director | Jan 30 | Open-market buy · P | +222,222 | $18.00 | +$4M | 1,513,664 |
| Gordon Carl L | Director | Jan 30 | Open-market buy · P | +222,222 | $18.00 | +$4M | 1,513,664 |
| Gordon Carl L | Director | Jan 30 | Derivative Conversion · C | +469,615 | — | — | 1,291,442 |
| Gordon Carl L | Director | Jan 30 | Derivative Conversion · C | +469,615 | — | — | 1,291,442 |
| Gordon Carl L | Director | Jan 30 | Derivative Conversion · C | +821,827 | — | — | 821,827 |
| Gordon Carl L | Director | Jan 30 | Derivative Conversion · C | +821,827 | — | — | 821,827 |
Loading...